Abstract
Monoclonal and polyclonal antibodies against placental alkaline phosphatase (PLAP) were evaluated for tumour immunolocalization of human PLAP-producing Hep 2 tumours in nude mice. The antibodies were labelled with 125I and injected i.p. in mice with developing Hep 2 tumours. The distribution of 125I-anti PLAP in various tissues showed that the labelled antibody was enriched in the tumour, the mean concentration ratio being 7.1 and 6.8 for polyclonal and monoclonal antibodies, respectively. A PLAP negative tumour (RD) showed a mean ratio of 1.2. There was a positive correlation between PLAP content and uptake of labelled antibody in the tumours. Hep 2 tumour cells in tissue culture showed 100% positivity for PLAP, while imprints of the tumour after passage in nude mice showed 40-50% positivity. PLAP offers potential as a useful marker for localizing tumours in humans.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Jeppsson, A., Wahren, B., Millán, J. et al. Tumour and cellular localization by use of monoclonal and polyclonal antibodies to placental alkaline phosphatase. Br J Cancer 49, 123–128 (1984). https://doi.org/10.1038/bjc.1984.23
Issue Date:
DOI: https://doi.org/10.1038/bjc.1984.23
This article is cited by
-
Combined low dose radio- and radioimmunotherapy of experimental HeLa Hep 2 tumours
European Journal of Nuclear Medicine and Molecular Imaging (2003)
-
Placental-like alkaline phosphatase in seminoma
Urological Research (1990)
